BENAXIBINE

Details

Stereochemistry	EPIMERIC
Molecular Formula	C12H15NO6
Molecular Weight	269.2506
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@@H]1COC(NC2=CC=C(C=C2)C(O)=O)[C@H](O)[C@H]1O

InChI

InChIKey=HLDUHCYBUVVDOT-GZBOUJLJSA-N

InChI=1S/C12H15NO6/c14-8-5-19-11(10(16)9(8)15)13-7-3-1-6(2-4-7)12(17)18/h1-4,8-11,13-16H,5H2,(H,17,18)/t8-,9+,10-,11?/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6985199 | https://www.ncbi.nlm.nih.gov/pubmed/6985188

response, while the remaining 7 patients were too far advanced to respond to these treatments. Benaxibine (also known as paraaminobenzoic acid-N-xyloside or K-247) was developed as an antitumor drug. Benaxibine participated in several clinical trials. However, for the positive application of the drug further studies were needed.

Originator

Approval Year

PubMed

Title	Date	PubMed
[Antitumor effects of p-aminobenzoic acid-N-xyloside Na--effects of single administration and combination with radiotherapy].	1982 Feb	6985191
[Effects of krestin and p-aminobenzoic-N-xyloside sodium salt on activities of drug-metabolizing enzymes and glutathione-related enzymes in rat liver].	1984 May	6144291
[Effects of intravenous hyperalimentation (IVH) on tumor growth and tumor response to P-aminobenzoic acid-N-xyloside sodium salt (K-247)].	1985 Jun 20	3932566

Sample Use Guides

In Vivo Use Guide

All patients were treated three or four times every day with oral administration of K-247 (BENAXIBINE) (600-800 mg/day).

Route of Administration: Oral

Name

Type

Language

BENAXIBINE

Official Name

English

P-(D-XYLOSYLAMINO)BENZOIC ACID

Common Name

English

benaxibine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C274